.'9 Early studies showed that these compounds are hypertensive.4 Recently, however, topical application of them was found to eventually lower the IOP in many animal species."7 Yet higher doses induce an initial increase of the IOP in rabbits' and monkeys67 and also cause aqueous flare in rabbits6 and cats.7
Prostaglandins (PGs) are formed in the eye'2 following various kinds of stimulation and are thought to mediate inflammatory responses.3 Among several types of PGs the PGE and F series have been extensively studied in relation to intraocular pressure (TOP). '9 Early studies showed that these compounds are hypertensive. 4 Recently, however, topical application of them was found to eventually lower the IOP in many animal species."7 Yet higher doses induce an initial increase of the IOP in rabbits' and monkeys67 and also cause aqueous flare in rabbits6 and cats.7
More recently the effects of PGF2a8 and its isopropyl ester9 on the human eye have been examined; and these PGs were found, as in animal eyes, to reduce the TOP. However, several side effects such as initial hypertension from higher doses, conjunctival hyperaemia, headache, and ocular smarting were noted. Thus the clinical usefulness of these PGs as hypotensive agents is limited, as has already been pointed out. ' During the course of biochemical experiments on PG synthesis in ocular tissues we found that PGD2 is the major PG formed in the rat ocular system."' This PG has been also reported to be synthesised in the rabbit eye. ' Results Fig. 1 shows the effect of topical application of 50 jsg of PGD2, PGE2, or PGF2a on IOP. The effects of PGE2 and PGF20 at this dose were biphasic, as have been reported by several authors,56 that is, application of either of these PGs resulted in an initial increase followed by a reduction in IOP. PGD2 on the other hand did not cause any increase but only reduced IOP. The reduction of IOP by PGD2 was observed within 30 min (but not at 15 min) and lasted throughout the observation period of 7 h. By 24 h, however, the IOP had returned to nearly its original level. The IOP at 24 h was 17-6±2-3 mmHg for the control and 17-7±2-0 mmHg for the treated eyes (n=9) (mean±SEM).
For four to seven hours after administration all three PGs reduced the IOP. As shown in Table 1 250 .tg of PGD2. However, PGE2 and PGF20 (50 Rig) caused strong conjunctival and iridal hyperaemia and irritation (eyes tightly closed) within 30 min after the application. These inflammatory responses lasted for at least four hours. Flare was also noted during one to two hours after the application of PGE2.
The effect of PGD2 on the protein content in the aqueous humour was also different from that of PGE2 or F20. At one hour after application PGD2 (50 [ig) did not induce any elevation of the aqueous protein, while PGE2 and F20 caused a 40-and 4-fold elevation respectively (Table 2) . PGD2 failed to increase the aqueous protein not only at 1 h but also at later times after its application. Protein contents at 2, 4, and 6 h were 0-72±0-08 mg/ml (mean±SEM, n=4), 0-65±0-08 (n=4), and 0-59±0-03 (n=4), respectively, and did not differ from the control level.
Discussion
The effect of PGD2 on IOP is distinct from that of PGE2 or PGF20. While PGD3 (an equivalent product from eicosapentaenoic acid to PGD2 from arachidonic acid) has also been reported in rabbits. , Species differences in PG-mediated responses are well documented. Therefore the results obtained in this study cannot necessarily be extended to the human eye. However, since PGD2 was found to be effective in reducing the IOP without causing any sign of inflammatory response, it is worth examining PGD2 or its analogues as therapeutic agents for the treatment of glaucoma in man.
